Contineum Therapeutics CTNM
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Contineum Therapeutics (CTNM) Business Model and Operations Summary
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
Key Insights
Contineum Therapeutics (CTNM) Core Market Data and Business Metrics
Latest Closing Price
$3.66Market Cap
$90.68 MillionTotal Outstanding Shares
25.87 Million SharesTotal Employees
41IPO Date
April 5, 2024SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
3565 General Atomics Court, Suite 200, San Diego, CA, 92121
Earnings Reports
Expected vs. Actual Quarterly Earnings-Per-Share & Revenue
Short Volume
Daily short volume activity identifies short-term trading pressure and potential price volatility
Revenue Breakdown
Distribution of revenue across unique business segments & geographies
Historical Stock Splits
| Execution Date | Split Amount |
|---|